List of Twirla drug patents

Twirla is owned by Agile.

Twirla contains Ethinyl Estradiol; Levonorgestrel.

Twirla has a total of 3 drug patents out of which 0 drug patents have expired.

Twirla was authorised for market use on 14 February, 2020.

Twirla is available in system;transdermal dosage forms.

The generics of Twirla are possible to be released after 26 August, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8747888 AGILE Dermal delivery device with in situ seal
Jul, 2028

(5 years from now)

US9050348 AGILE Dermal delivery device
Jul, 2028

(5 years from now)

US8246978 AGILE Dermal delivery device with reduced loss of its volatile components
Aug, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 14, 2023

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 14 February, 2020

Treatment: NA

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in